Proposed Cannabis Class Action Goes Up in Smoke
Warning message
The subscription service is currently unavailable. Please try again later.In Badesha v. Cronos Group, 2021 ONSC 4346, the court refused to certify an action alleging securities misrepresentation because there was no reasonable possibility that the alleged misrepresentations caused any loss. The plaintiff argued that thousands of alleged misrepresentations in the defendant’s financial statements should be treated as separate misrepresentations, but failed to establish—or even plead—that anyone relied on any one of them.
Many securities misrepresentation certification decisions focus on the predominance of individual issues (see our recent post on 0116064 B.C. Ltd. v. Alio Gold Inc., 2021 BCSC 540). Cronos Group is a reminder that a misrepresentation is not enough to clear the hurdle of a reasonable cause of action required for certification: someone must have allegedly relied on the misrepresentation. Negligence in the air is not enough to certify a class action.
The plaintiff in Badesha is a shareholder in Cronos, a Canadian medical and recreational cannabis company. Cronos delayed the release of annual filings in March 2020 to allow for review and audit of revenue recognition related to several 2019 transactions. Eventually, Cronos reissued restated MD&A and Interim Financial Statements for the first three quarters of 2019, correcting accounting errors that inappropriately counted wholesale transactions as revenue. The plaintiff brought the action on behalf of a proposed worldwide class of all past and current Cronos shareholders who acquired shares between the first alleged misrepresentation and the revision.
The plaintiff claimed to have identified 570 individual misrepresentations in Cronos’ financial documents for the first three quarters of 2019. The plaintiff then alleged that each alleged misrepresentation was reiterated by Cronos’ directors and officers and there were actually 7,449 individual misrepresentations. The plaintiff apparently wanted to increase the amount it might receive in damages if the claim succeeded by relying on thousands of individual alleged misrepresentations.
In a companion motion for leave to proceed under s. 138.3 of the Ontario Securities Act, the court held that none of the alleged individual misrepresentations could have had a material impact in the context of the company, its industry, or the market overall. The plaintiff would have to show that each of the 7,449 alleged individual misrepresentations was separately and distinctly material. But the evidence did not even attempt to meet that standard (a motion under s. 138.3 involves a more detailed assessment of the merits of case than a certification motion). The proposed action therefore failed to meet the criteria of s. s. 138.3.
Similarly, because the plaintiffs had not alleged that anyone relied on any individual misrepresentation, they could not meet the requirement under the Class Proceedings Act to plead a reasonable cause of action
420 Intel is Your Source for Marijuana News
420 Intel Canada is your leading news source for the Canadian cannabis industry. Get the latest updates on Canadian cannabis stocks and developments on how Canada continues to be a major player in the worldwide recreational and medical cannabis industry.
420 Intel Canada is the Canadian Industry news outlet that will keep you updated on how these Canadian developments in recreational and medical marijuana will impact the country and the world. Our commitment is to bring you the most important cannabis news stories from across Canada every day of the week.
Marijuana industry news is a constant endeavor with new developments each day. For marijuana news across the True North, 420 Intel Canada promises to bring you quality, Canadian, cannabis industry news.
You can get 420 Intel news delivered directly to your inbox by signing up for our daily marijuana news, ensuring you’re always kept up to date on the ever-changing cannabis industry. To stay even better informed about marijuana legalization news follow us on Twitter, Facebook and LinkedIn.